Skip to main content
. 2020 Jun 19;9(6):1496. doi: 10.3390/cells9061496

Figure 2.

Figure 2

SMARCA4 and SMARCA2 expression in SCCOHT. (A) Representative SMARCA4 and SMARCA2 immunohistochemistry in a SMARCA4 mutated SCCOHT and in the one SMARCA4 wild-type. Tumor harboring concomitant ARID1A and ARID1B mutations (IGR-03). (B) Real-time RT-PCR for SMARCA2 in patient tumor samples from this study and in a SCCOHT cell line (BIN-67); expression levels are normalized to three housekeeping genes (YWHAZ/GUSB/HPRT1). (C) Western blot showing expression of several SWI/SNF subunits in SCCOHT cell lines (BIN-67, SCCOHT-1) compared to MRT (G401, MON, TTC709), SMARCA4-mutated lung cancer (H1299), high-grade endometrioid adenocarcinoma of the ovary (SKOV3) and neuroendocrine small cell lung cancer (DMS79) cell lines. (D) Results of Sanger sequencing of the SMARCA2 promoter insertional polymorphism sites, and an example of a heterozygous polymorphism status (−1321 site) in BIN-67 cells. (E) Representative IHC for SOX2 in SCCOHT and a positive control (SOX2-positive MRT) in patient FFPE tumor samples.